How Eli Lilly Makes Money

How It Started

Problem: In May 1876, the pharmaceutical market was dominated by unproven miracle medicines of the era. Lilly began the company out of frustration with the ineffective medications of the time. The industry desperately needed scientific rigor and standardization.

Solution: Eli Lilly founded his company on Pearl Street in Indianapolis in 1876, with a mission to discover and sell scientifically sound formulas that would help alleviate human suffering. Colonel Eli Lilly launched the firm to combat adulterated Civil War–era drugs, focusing on scientific controls, consistent dosing, and physician collaboration. Early products included gelatin-coated pills and capsules. Lilly was an advocate of federal regulation of the pharmaceutical industry, and many of his suggested reforms were enacted into law in 1906, resulting in the creation of the Food and Drug Administration. He was also among the pioneers of the concept of prescriptions.

Target Audience: By the early 1900s, Eli Lilly was a family-owned ethical drug company, operating under a policy of advertising and selling only to doctors and pharmacists. It made neither patent medicines nor extravagant claims about its products. This targeted approach focused on healthcare professionals rather than the general public.

Competitive Advantage

Eli Lilly built its competitive advantage through several key differentiators:

Manufacturing Innovation: In 1909, Eli Lilly, grandson of the company’s founder, introduced a method for blueprinting manufacturing tickets, which created multiple copies of a drug formula and helped eliminate manufacturing and transcription errors. In the 1920s, Eli introduced the new concept of straight-line production to the pharmaceutical industry, where raw materials entered at one end of the facility and the finished product came out the other end. Under Eli’s supervision, the design for Building 22, a new five-floor plant that opened in Indianapolis in 1926, implemented the straight-line concept to improve production efficiency and lower production costs.
Research Infrastructure: Eli Lilly and Company became one of the first pharmaceutical firms of its kind to staff a dedicated research department and put into place numerous quality-assurance measures.
Scale and Expertise: A pivotal moment in its history was the mass production of insulin in 1923, followed by the polio vaccine in 1955, which underscored its commitment to addressing critical health challenges. Leadership in insulin production during the 1920s gained Lilly respect in the scientific community, enabling the company to attract first-rate scientists.
Modern Product Portfolio: The company’s recent success centers on incretin therapies such as Mounjaro and Zepbound, positioning Lilly as a leader in high-demand therapeutic areas.

Marketing Technique

Eli Lilly employs a specialized, multi-channel marketing approach tailored to the pharmaceutical industry.

Physician-Focused Marketing

Following its heritage as an ethical pharmaceutical company, Lilly maintains direct relationships with healthcare providers through sales representatives, medical conferences, and continuing education programs. This approach emphasizes clinical evidence and scientific data rather than consumer advertising.

Patient Access Programs

Lilly launched the Lilly Insulin Value Program, providing a $35 copay card to help with the cost of certain medicines, regardless of insurance status. The Lilly Diabetes Solution Center opened to assist people who need help paying for their Lilly insulin in the United States. These initiatives build brand loyalty and improve patient access.

Innovation and Thought Leadership

The first Lilly Gateway Labs opened in San Francisco as a shared innovation space for scientific start-ups discovering new medicines. The model has since expanded to include multiple locations across the United States and China. This positions Lilly as a forward-thinking innovation partner.

Eli Lilly generates revenue primarily through the development, manufacturing, and sale of prescription pharmaceuticals and biologics. The company’s anticipated 2024 full-year worldwide revenue was approximately $45.0 billion, representing a significant 32% growth compared to the previous year. The company’s primary products are tirzepatide, sold under the brand names Mounjaro and Zepbound, for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea, accounting for 37% of 2024 revenue. The company also derives substantial income from oncology, neuroscience, cardiovascular, and immunology therapeutic areas through a diverse pipeline of patent-protected drugs.

Market Share

While Eli Lilly does not publicly disclose a single unified market share percentage across all therapeutic categories, its position in the global pharmaceutical industry is substantial.

Metric	Value/Ranking
Most Valuable Pharmaceutical Company	Ranked as the most valuable pharmaceutical company worldwide
Market Capitalization	$1 trillion, the first healthcare company in the world to reach this milestone
Largest Biomedical Companies by Revenue	Ranked 4th
Fortune 500 Ranking	Ranked 100th
2024 Revenue	Approximately $45.0 billion
Geographic Presence	Products sold in approximately 125 countries

Business Model Canvas of Eli Lilly

Value Proposition: Scientifically rigorous, innovative pharmaceutical therapies that address critical unmet medical needs in diabetes, obesity, oncology, neuroscience, and cardiovascular diseases, backed by patent protection and clinical evidence.

Revenue Streams: Pharmaceutical sales, including prescription drugs and biologics, licensing agreements, and patient assistance programs. Incretin therapies like tirzepatide dominate current revenue generation.

Key Resources: Eli Lilly and Company employs approximately 38,000 people worldwide, with over 7,600 employees in eight different countries engaged in research and development. Additional key resources include proprietary manufacturing facilities, a robust patent portfolio, and established global distribution networks.

Key Partners: Academic research institutions, Contract Research Organizations, manufacturing partners, healthcare providers, and regulatory bodies. The Lilly Endowment, a charitable foundation organized in 1937 by the founding family, owns 10% of the company.

Customer Segments: Healthcare providers including physicians and hospitals, patients seeking treatment for chronic diseases, health insurance companies, and government health agencies.

Channels: Direct sales representatives to physicians, hospital partnerships, retail and mail-order pharmacies, telemedicine platforms, and patient assistance programs.

Cost Structure: Research and development remains the largest expense category, with R&D intensity exceeding 20% of sales in 2024. Additional costs include manufacturing, regulatory compliance, clinical trials, and marketing to healthcare professionals.

Conclusion: Is It a Viable Business?

Eli Lilly represents one of the most viable pharmaceutical business models in the world. The company’s trajectory from a single-room laboratory in 1876 to a $1 trillion market-cap enterprise demonstrates remarkable resilience and strategic excellence. The company is ranked 4th on the list of largest biomedical companies by revenue and stands as the most valuable pharmaceutical company worldwide.

The business model’s viability is underpinned by several factors: a diverse therapeutic portfolio addressing massive global health challenges, strong intellectual property protections through patents, recurring revenue from chronic disease treatments, a proven ability to innovate and bring breakthrough drugs to market, and pricing power in regulated markets. Profits from insulin and other new products enabled the company to survive the Great Depression of the 1930s without laying off a single employee, showcasing financial resilience across economic cycles.

However, challenges remain, including increasing drug development costs, pricing pressures from regulators and payers, patent expirations, supply chain complexities for GLP-1 therapies, and competition from rivals such as Novo Nordisk. Despite these headwinds, Eli Lilly’s dominance in high-growth markets like incretin therapies, combined with its enormous R&D investment and manufacturing sophistication, positions it as a viable enterprise for decades to come.